Interim efficacy of bedaquiline-containing regimen in treatment of MDR/XDR-TB: a prospective cohort study
Author:
Affiliation:

1.Department of Tuberculosis Diagnosis and Treatment, Changsha Central Hospital, University of South China, Changsha 410007, China;2.Department of Tuberculosis, Chenzhou Second People's Hospital, Chenzhou 423000, China

Clc Number:

R521

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    Objective To evaluate the efficacy and safety of bedaquiline (BDQ-containing) regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB)/extensively drug-resistant tuberculosis (XDR-TB), and provide clinical data for the use of BDQ in drug-resistant TB patients in China. Methods Clinical data of tuberculosis patients receiving BDQ-containing regimen in a hospital from March 2018 to September 2019 were collected, efficacy and adverse reactions during treatment were analyzed. Results Sixty-nine patients were enrolled, 10 (14.5%) of whom had XDR-TB, 63 cases (91.3%) completed 24 weeks of BDQ-containing treatment, two patients died of cardiac arrest and respiratory failure during treatment, three were transferred, one was lost to follow-up, 39 patients (56.5%) reported 108 times of adverse events, most adverse events were classified as grade 1 or grade 2 (75 times, 69.4%), and the most common grade 3 and above adverse events were QT interval prolongation. 29 cases (46.0%) were positive in sputum culture at baseline, the negative conversion rates of sputum culture at week 8, 12 and 24 were 93.1% (27 cases), 100.0% (29 cases) and 93.1% (27 cases) respectively, sputum culture of 2 patients returned to positive at week 24; the median time of negative conversion of sputum culture was 24 days (interquartile interval: 14-61 days). Among 52 patients with pulmonary cavity, 48 (92.3%) completed 24 weeks of BDQ-containing treatment, the cavity closure rates at week 12 and 24 were 37.5% and 64.6% respectively. Conclusion Compared with the traditional treatment regimen, BDQ-containing treatment regimen for 24 weeks can improve the negative conversion rate of sputum culture and cavity closure rate in patients with MDR/XDR-TB, but attention should be paid to the monitoring and management of QT interval.

    Reference
    Related
Get Citation

裴异,陈检才,封文军,等.含贝达喹啉方案治疗耐多药/广泛耐药结核病中期疗效前瞻性队列研究[J].中国感染控制杂志英文版,2021,(12):1102-1108. DOI:10.12138/j. issn.1671-9638.20211484.
Yi PEI, Jian-cai CHEN, Wen-jun FENG, et al. Interim efficacy of bedaquiline-containing regimen in treatment of MDR/XDR-TB: a prospective cohort study[J]. Chin J Infect Control, 2021,(12):1102-1108. DOI:10.12138/j. issn.1671-9638.20211484.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:May 27,2021
  • Revised:
  • Adopted:
  • Online: April 26,2024
  • Published: